Dry macular degeneration is a chronic eye disease that slowly breaks down the macula, the small central area of the retina responsible for sharp, straight-ahead vision. It accounts for roughly 80% of all age-related macular degeneration (AMD) cases and progresses gradually over years, unlike its less common but more aggressive counterpart, wet AMD. While it rarely causes sudden vision loss, it can significantly erode your ability to read, drive, and recognize faces over time.
What Happens Inside the Eye
The retina lines the back of your eye and contains millions of light-sensitive cells called photoreceptors. These cells depend on a thin layer of support cells beneath them, the retinal pigment epithelium (RPE), which nourishes the photoreceptors, removes waste, and forms a barrier between the retina and the blood vessels that supply it with oxygen.
In dry AMD, this waste-removal system starts to fail. Yellow deposits called drusen accumulate between the RPE and the underlying blood supply. Small drusen are common with aging and don’t necessarily cause problems, but as they grow larger and more numerous, they signal that the RPE is struggling. Waste material also builds up inside the RPE cells themselves (called lipofuscin) and above them in the space near the photoreceptors. Over time, this buildup triggers an immune response. The body sends inflammatory cells into the outer retina, which can accelerate damage to the RPE. When enough RPE cells die, the photoreceptors they support die too, and vision in that area is permanently lost.
Stages of the Disease
Dry AMD is classified into three stages based on the size and number of drusen and whether any retinal tissue has started to waste away.
Early dry AMD is defined by the presence of small drusen beneath the retina. Most people at this stage have no noticeable vision changes and are unaware anything is wrong. The condition is typically discovered during a routine eye exam.
Intermediate dry AMD involves larger drusen and sometimes pigmentary changes in the RPE, visible as dark or light spots on an eye exam. Some people begin to notice mild blurriness or need brighter light for reading, though many still have no obvious symptoms.
Advanced dry AMD, called geographic atrophy (GA), is the late stage. Patches of RPE and photoreceptors die off completely, leaving well-defined areas of retinal thinning. This produces blind spots in central vision and makes it difficult to read, drive, see in dim light, or distinguish colors, which can appear drab or washed out. Geographic atrophy tends to start around the center of the macula and expand outward over months to years.
Symptoms to Watch For
Blurred vision is the most common early symptom, though it can be subtle enough to dismiss. One characteristic warning sign is that straight lines begin to appear wavy or crooked, a distortion you might notice while looking at door frames, blinds, or the lines on a page. As the disease progresses, you gradually lose central vision. You can still see objects off to the side, but the area directly ahead becomes increasingly hazy or blank.
In geographic atrophy, the symptoms are more pronounced. A dark spot or blind area develops in your central field of view. Reading requires larger print or magnification. Recognizing faces becomes harder. Colors lose their vibrancy. Low-light environments become particularly challenging, making restaurants and movie theaters difficult to navigate.
Who Is at Risk
Age is the strongest risk factor. The likelihood of developing AMD rises significantly after 50 and continues climbing with each decade. Smoking is the most well-established modifiable risk factor, roughly doubling or tripling the odds depending on how long and how heavily a person has smoked.
Genetics also play a major role. Variations in genes related to the complement system, part of the body’s immune defense, are strongly linked to AMD risk. The CFH gene is one of the most studied, along with changes in a region of chromosome 10 involving two genes called ARMS2 and HTRA1. Other genetic factors involve genes that help transport and process HDL cholesterol. Having a parent or sibling with AMD increases your own risk substantially.
Beyond age, smoking, and genetics, other factors that raise risk include high blood pressure, heart disease, obesity, a diet high in saturated fat or low in antioxidants and zinc, and prolonged exposure to ultraviolet light.
How It Is Diagnosed
An eye doctor can spot drusen during a dilated eye exam, often before you notice any symptoms. Two imaging technologies are especially useful for tracking the disease. Optical coherence tomography (OCT) takes cross-sectional scans of the retina, showing drusen deposits, areas of thinning, and disruptions to the photoreceptor layer with microscopic detail. Disruption of the junction between photoreceptor segments on OCT strongly correlates with reduced retinal sensitivity, making it a reliable marker of functional damage.
Fundus autofluorescence (FAF) captures the natural glow of certain waste products in the RPE, creating a map of healthy and unhealthy tissue. Areas that glow too brightly or too dimly both correspond to reduced retinal function. Near-infrared autofluorescence may be particularly useful for detecting retinal changes in the earlier stages of dry AMD, before vision loss becomes obvious. Together, these tools let your doctor monitor progression over time and catch changes that a standard exam might miss.
Can It Turn Into Wet AMD?
Dry AMD can convert to wet AMD, in which abnormal blood vessels grow beneath the retina and leak fluid or blood, causing rapid vision loss. The conversion rate depends on the stage. A large registry analysis found that about 2% of early-stage dry AMD cases converted to wet AMD, compared to 6.1% for intermediate and 6.7% for advanced cases. While those percentages sound modest, they underscore why regular monitoring matters, especially if you have intermediate or advanced disease. Catching the wet form early makes treatment far more effective.
Treatment and Slowing Progression
There is no way to reverse the damage dry AMD has already caused, but there are meaningful steps to slow it down.
AREDS2 Supplements
The most widely recommended intervention for people with intermediate dry AMD or advanced disease in one eye is the AREDS2 supplement formula, based on a major clinical trial conducted by the National Eye Institute. The daily formulation includes 500 mg of vitamin C, 180 mg of vitamin E, 80 mg of zinc, 2 mg of copper (to prevent a zinc-related deficiency), 10 mg of lutein, and 2 mg of zeaxanthin. This specific combination was shown to reduce the risk of progressing to advanced AMD. These supplements are available over the counter but are not beneficial for people with only early-stage disease.
Treatments for Geographic Atrophy
For the first time, two injectable medications are available that target geographic atrophy. Both work by inhibiting part of the complement system, the same immune pathway implicated in the disease’s progression. They are administered as injections into the eye and have been shown to slow the rate at which atrophic areas expand. However, they do not restore lost vision or improve visual function that has already declined. Their benefit is in slowing further damage, which makes earlier detection of geographic atrophy more important than ever.
Lifestyle Measures
Quitting smoking is the single most impactful lifestyle change for reducing AMD risk and slowing progression. A diet rich in leafy greens, fish, and colorful fruits and vegetables supplies the antioxidants and omega-3 fatty acids linked to better retinal health. Managing blood pressure, maintaining a healthy weight, wearing UV-blocking sunglasses, and exercising regularly all contribute to lowering risk as well. None of these measures guarantee prevention, but they address several of the modifiable factors that drive the disease forward.